{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:31Z","timestamp":1793736571809,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02745-1","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:30:16Z","timestamp":1746210616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Hiroki","family":"Teragawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikage","family":"Oshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"39","key":"2745_CR1","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"22","key":"2745_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2745_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"2745_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"2745_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"15","key":"2745_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"2745_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"2745_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"37","key":"2745_CR9","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"12","key":"2745_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"2745_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643\u201358.","journal-title":"Circulation"},{"issue":"10","key":"2745_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"10","key":"2745_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","volume":"21","author":"C Wojcik","year":"2019","unstructured":"Wojcik C, Warden BA. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. Curr Cardiol Rep. 2019;21(10):130.","journal-title":"Curr Cardiol Rep"},{"key":"2745_CR14","doi-asserted-by":"publisher","first-page":"175394472093938","DOI":"10.1177\/1753944720939383","volume":"14","author":"M Sano","year":"2020","unstructured":"Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis. 2020;14:1753944720939383.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"3","key":"2745_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10741-020-10041-1","volume":"26","author":"M Dutka","year":"2021","unstructured":"Dutka M, Bobinski R, Ulman-Wlodarz I, Hajduga M, Bujok J, Pajak C, Cwiertnia M. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Fail Rev. 2021;26(3):603\u201322.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2745_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12933-021-01295-6","volume":"20","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, et al. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovasc Diabetol. 2021;20(1):105.","journal-title":"Cardiovasc Diabetol"},{"key":"2745_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101337","volume":"54","author":"N D'Onofrio","year":"2021","unstructured":"D\u2019Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, Panarese I, Petrella L, Fanelli M, Modugno P, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54: 101337.","journal-title":"Mol Metab"},{"issue":"1","key":"2745_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","volume":"22","author":"C Sardu","year":"2023","unstructured":"Sardu C, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22(1):80. https:\/\/doi.org\/10.1186\/s12933-023-01814-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2745_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","volume":"21","author":"R Marfella","year":"2023","unstructured":"Marfella R, Sardu C, D\u2019Onofrio N, Fumagalli C, Scisciola L, Sasso FC, Siniscalchi M, Marfella LV, D\u2019Andrea D, Minicucci F, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71.","journal-title":"BMC Med"},{"key":"2745_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106448","volume":"184","author":"R Marfella","year":"2022","unstructured":"Marfella R, Scisciola L, D\u2019Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M, et al. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. 2022;184: 106448.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2745_CR21","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","volume":"39","author":"S Verma","year":"2016","unstructured":"Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39(12):e212\u20133.","journal-title":"Diabetes Care"},{"issue":"1","key":"2745_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2745_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2745_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1253\/circrep.CR-19-0018","volume":"1","author":"T Sakai","year":"2019","unstructured":"Sakai T, Miura S. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction\u2014novel prospective cohort study. Circ Rep. 2019;1(7):286\u201395.","journal-title":"Circ Rep"},{"key":"2745_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01380-w","author":"K Kusunose","year":"2021","unstructured":"Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, et al. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial. Cardiovasc Diabetol. 2021. https:\/\/doi.org\/10.1186\/s12933-021-01380-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2745_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jjcc.2024.02.002","volume":"84","author":"K Kusunose","year":"2024","unstructured":"Kusunose K, Imai T, Tanaka A, Doi M, Koide Y, Fukumoto K, Kadokami T, Ohishi M, Teragawa H, Ohte N, et al. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: a sub-analysis of the PROTECT trial. J Cardiol. 2024;84(4):246\u201352.","journal-title":"J Cardiol"},{"issue":"4","key":"2745_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00592-021-01823-6","volume":"59","author":"A Rai","year":"2022","unstructured":"Rai A, Connelly KA, Verma S, Mazer CD, Teoh H, Ng MY, Roifman I, Quan A, Pourafkari M, Jimenez-Juan L, et al. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetol. 2022;59(4):575\u20138.","journal-title":"Acta Diabetol"},{"issue":"18","key":"2745_CR28","doi-asserted-by":"publisher","first-page":"14661","DOI":"10.18632\/oncotarget.24482","volume":"9","author":"PY Wu","year":"2018","unstructured":"Wu PY, Huang JC, Chen SC, Chen LI. Type 2 diabetes mellitus-related changes in left ventricular structure and function in patients with chronic kidney disease. Oncotarget. 2018;9(18):14661\u20138.","journal-title":"Oncotarget"},{"issue":"1","key":"2745_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41371-022-00751-4","volume":"37","author":"JP Law","year":"2023","unstructured":"Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J Hum Hypertens. 2023;37(1):1\u201319.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"2745_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101447","volume":"49","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Okada Y, Torimoto K, Kamei N, Hirai H, Kono T, Sugimoto K, Teragawa H, Taguchi I, Maruhashi T, et al. Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: a randomized clinical trial (PROCEED). Diabetes Metab. 2023;49(4): 101447.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2745_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-020-01065-w","volume":"19","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K. investigators Pt: Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Cardiovasc Diabetol. 2020;19(1):85.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2745_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s13340-024-00723-8","volume":"15","author":"R Bouchi","year":"2024","unstructured":"Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, et al. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version). Diabetol Int. 2024;15(3):327\u201345.","journal-title":"Diabetol Int"},{"issue":"3","key":"2745_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"2745_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jacc.2016.12.037","volume":"69","author":"SS Mitter","year":"2017","unstructured":"Mitter SS, Shah SJ, Thomas JD. A test in context: E\/A and E\/e\u2019 to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol. 2017;69(11):1451\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2745_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/FJC.0b013e31821823d9","volume":"57","author":"S de Jong","year":"2011","unstructured":"de Jong S, van Veen TA, de Bakker JM, Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. 2011;57(5):522\u201335.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2745_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1248\/bpb.b18-00728","volume":"42","author":"T Takasu","year":"2019","unstructured":"Takasu T, Yokono M, Tahara A, Takakura S. In vitro pharmacological profile of ipragliflozin, a sodium glucose co-transporter 2 inhibitor. Biol Pharm Bull. 2019;42(3):507\u201311.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"2745_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","volume":"130","author":"A Tahara","year":"2016","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016;130(3):159\u201369.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"2745_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ehjcvp\/pvac059","volume":"9","author":"A Tanaka","year":"2022","unstructured":"Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, et al. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: A multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2022;9(2):165\u201372.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"2745_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"3 Pt 3","key":"2745_CR40","doi-asserted-by":"publisher","first-page":"100s","DOI":"10.1093\/ajh\/1.3.100S","volume":"1","author":"WF Graettinger","year":"1988","unstructured":"Graettinger WF, Longfellow JV, Klein RC, Weber MA. Diastolic blood pressure and left ventricular filling. Am J Hypertens. 1988;1(3 Pt 3):100s\u20132s.","journal-title":"Am J Hypertens"},{"issue":"2","key":"2745_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41440-022-01105-w","volume":"46","author":"Y Matsuzawa","year":"2023","unstructured":"Matsuzawa Y. Is diastolic blood pressure key to detecting risk and preventing heart failure with preserved ejection fraction? Hypertens Res. 2023;46(2):534\u20136.","journal-title":"Hypertens Res"},{"issue":"8","key":"2745_CR42","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.2011.1201","volume":"306","author":"GC Kane","year":"2011","unstructured":"Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306(8):856\u201363.","journal-title":"JAMA"},{"issue":"3","key":"2745_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/CIRCHEARTFAILURE.112.000216","volume":"6","author":"MR Zile","year":"2013","unstructured":"Zile MR, Kjellstrom B, Bennett T, Cho Y, Baicu CF, Aaron MF, Abraham WT, Bourge RC, Kueffer FJ. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail. 2013;6(3):508\u201316.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"2745_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000535297","volume":"149","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Dai M, Huang T, Chen B, Xiang Z, Tang J, Zheng M, Guo L. Association between BMI and efficacy of SGLT2 inhibitors in patients with heart failure or at risk of heart failure: a meta-analysis based on randomized controlled trials. Cardiology. 2024;149(2):104\u201316.","journal-title":"Cardiology"},{"issue":"1","key":"2745_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12933-024-02478-7","volume":"23","author":"Y Mori","year":"2024","unstructured":"Mori Y, Komura T, Adomi M, Yagi R, Fukuma S, Kondo N, Yanagita M, Duru OK, Tuttle KR, Inoue K. Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study. Cardiovasc Diabetol. 2024;23(1):372.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2745_CR46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/biomedicines9080904","volume":"9","author":"C Sardu","year":"2021","unstructured":"Sardu C, D\u2019Onofrio N, Torella M, Portoghese M, Mureddu S, Loreni F, Ferraraccio F, Panarese I, Trotta MC, Gatta G, et al. Metformin therapy effects on the expression of sodium-glucose cotransporter 2, leptin, and SIRT6 levels in pericoronary fat excised from pre-diabetic patients with acute myocardial infarction. Biomedicines. 2021;9(8):904.","journal-title":"Biomedicines"},{"key":"2745_CR47","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13681","author":"C Andrade","year":"2020","unstructured":"Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.20f13681.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2745_CR48","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","volume":"85","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, Makaya M, Murohara T, Node K, Saito Y, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circ J. 2021;85(12):2252\u201391.","journal-title":"Circ J"},{"key":"2745_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.002917","author":"JS Dahl","year":"2015","unstructured":"Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, Pellikka PA. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc Imaging. 2015. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.002917.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"8","key":"2745_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29352","volume":"10","author":"G Chen","year":"2024","unstructured":"Chen G, Ding P, Yang L, Liu X, Yu D, Yue W. Left ventricular ejection fraction <60 % is associated with short-term functional disability in patients of acute ischemic stroke. Heliyon. 2024;10(8): e29352.","journal-title":"Heliyon"},{"issue":"12","key":"2745_CR51","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925\u201366.","journal-title":"Diabetologia"},{"issue":"3","key":"2745_CR52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","volume":"149","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jensen TJ, Rasmussen S, Marstrand PE, Petrie MC, Shah SJ, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2023;149(3):204\u201316.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02745-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:02:48Z","timestamp":1746216168000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02745-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol was approved by local certified review boards, and the trial was conducted in compliance with the Declaration of Helsinki and the Clinical Trial Act of Japan. After the patients were initially screened for eligibility based on their prior medical records, they were adequately informed of the trial plan and provided written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.T. has received honoraria from Abbott Medical Japan, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Medtronic, and Nihon Medi-Physics. A.T. has received honoraria from Boehringer Ingelheim Japan, Mochida, and Amgen; research funding from Bristol Myers Squibb and Novo Nordisk; A.T. is an Editorial Board member of the journal and not involved in handling this manuscript during the submission and review processes. K.T. has received outsourcing fees from Organization for Clinical Medicine Promotion. N.K. has received honoraria from Sumitomo, Novo Nordisk, Taisho, Eli Lilly Japan, Bayer, Boehringer Ingelheim, Kowa, Daiichi Sankyo, Astellas, MSD, Teijin, Eisai, Novartis, and Mitsubishi Tanabe. M.S. has received honoraria from Astellas Pharma Inc. Y.O. has received honoraria from Astellas, MSD, Mitsubishi Tanabe, Bayer, Novo Nordisk, Kowa and Eli Lilly Japan. K.N. has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, Otsuka; Research grant from Astellas, Bayer, Boehringer Ingelheim Japan, Fuji Yakuhin, Mochida, Novartis; Scholarship from Abbott Medical, Boehringer Ingelheim Japan, Daiichi Sankyo Healthcare, Mitsubishi Tanabe, Teijin. All other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}